Stockhead’s Top 10 at shortly-before-11-ish, published surprisingly close to on time, considering I was still shaking the tiles off the roof with my snoring when the market doors opened today.

It highlights the best (and sometimes worst) performing ASX stocks in morning trade using live, fresh out of the deep-fryer data.

It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.

The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has started trading.



Stocks highlighted in yellow have made market-moving announcements (click headings to sort).

Wordpress Table Plugin


Starpharma (ASX:SPL) is surging early on news that it has positive interim clinical data from Starpharma’s Phase 1/2 clinical trial of DEP irinotecan, involving patients with colorectal or ovarian cancer.

Etherstack (ASX:ESK) – is flying for a second day after the company signed an agreement with Telstra to trial and evaluate Etherstack’s innovative Mission Critical (MCX) 3GPP standards compliant Interworking function.

Widgie Nickel (ASX:WIN) – up on news that the high-grade nickel hit (reported already as a pXRF reading) has been confirmed by assay, with one hole returning 9.14m @ 10.44% Ni, 0.75% Cu, 0.13% Co, 1.93g/t 3PGE from 330.00m, including 2.61m @ 18.88% Ni, 0.48% Cu, 0.23% Co, 0.65g/t 3PGE from 335.44m.

James Bay Minerals (ASX:JBY) – The latest lithium new kid on the block is up after listing successfully yesterday.

Apollo Minerals (ASX:AON) – up on news of a Bonanza Grade gold hit, including visible gold in quartz veining assaying 429g/t Au and 125g/t Au at the A1 Prospect in rock chip spoil samples adjacent to historical trenching.

Burgundy Diamond Mines (ASX:BDM) – Up after revealing sales of ~US$90 million for Q3 CY2023 to date, up from ~US$81 million on pcp.

Australian Critical Minerals (ASX:ACM) – Up on no news.



Stocks highlighted in yellow have made market-moving announcements (click headings to sort).

Wordpress Table Plugin


Firebrick Pharma (ASX:FRE) – falling hard this morning on news that its phase 3 trial of Nasodine Nasal Spray as a treatment for the common cold “did not meet its primary endpoint”.

92 Energy (ASX:92E) – down on news of hitting a new parallel structure with intense hydrothermal alteration, uranium pathfinders and 2.2m of 0.08% eU3O8, incl. 0.5m of 0.12% eU3O8 at its Gemini prospect.

Nickelsearch (ASX:NIS) – currently giving back a chunk of yesterday’s stellar gains.